1

Alzheimers Association Research Initiatives

Dean M. Hartley, Ph.D. Director of Scientific Director

Alzheimers Association

2

Our vision is a world without Alzheimers disease

Our goals: Advance research Provide care

and support Increase Concern &

Awareness Public Policy &

Advocacy Efforts

3

Alzheimers Association is the global leader in Alzheimer research.

Amyloid Imaging Taskforce (AIT)

A New Research Ini/a/ve Down Syndrome & Alzheimers disease

ALZHEIMERS ASSOCIATION, LINDA CRNIC INSTITUTE FOR DOWN SYNDROME, AND GLOBAL DOWN SYNDROME

FOUNDATION LAUNCH NEW RESEARCH GRANTS PROGRAM

Initial $1.2 million aims to fund research to better treat Alzheimers in people with Down syndrome and the

general population

5

The challenge began 100 years ago November 1906: Alois Alzheimer

presented first case in Germany 51-year-old Auguste D. had

profound memory loss, confusion, language difficulty, unfounded suspicions about husband and hospital staff

Her young age made Alzheimer think Auguste had a rare disease associated with middle age

tangles

plaques

6

Normal Alzheimers disease

Continuum of Alzheimers Disease

Adapted from Sperling et al. 2011

7 www.alz.org

The Dominantly Inherited Alzheimer Network (DIAN) Observational Trial

0.4

0.6

0.8

1

1.2

1.4

-30 -20 -10 0 10 20

Muta/on Carriers

Non-Carriers

Logical Memory Beta-Amyloid Deposition

Est. Years Before Clinical Onset Est. Years Before Clinical Onset

0

5

10

15

20

-30 -20 -10 0 10 20

Muta/on Carriers

Non-Carriers

Bateman et al. (2012) N Eng J Med 367: 795- 804

8

DIAN-Trial Unit Alzheimers Association help to initiate the

trial: $4.2M grant Three simultaneous trials to test potential

therapies: Gantenerumab (Roche, Monoclonal antibody to AB) Solaneuzumab (Lilly, Monoclonal antibody to AB) TBD

Adaptive Trial Design Condenses the timeline Trial began March, 2013

9

Genetic Links to Alzheimers and Down Syndrome

10

NATURE REVIEWS | DRUG DISCOVERY VOLUME 11 | SEPTEMBER 2012 | 655